Skip to main content
Journal cover image

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

Publication ,  Journal Article
Boyer, MJ; Gu, L; Wang, X; Kelsey, CR; Yoo, DS; Onaitis, MW; Dunphy, FR; Crawford, J; Ready, NE; Salama, JK
Published in: Lung Cancer
August 2016

To determine the feasibility and toxicity of radiation therapy, delivered either as definitive treatment or following surgery, following neo-adjuvant immune checkpoint inhibition for locally advanced NSCLC sixteen patients who received neo-adjuvant chemotherapy including ipilimumab as part of a phase II study were identified. Patients were analyzed by intent of radiation and toxicity graded based on CTCAE 4.0. There were seven patients identified who received definitive radiation and nine who received post-operative radiation. There was no grade 3 or greater toxicity in the definitive treatment group although one patient stopped treatment early due to back pain secondary to progression outside of the treatment field. In the post-operative treatment group, one patient required a one week break due to grade 2 odynophagia and no grade 3 or greater toxicity was observed. In this study of radiation as definitive or post-operative treatment following neo-adjuvant chemotherapy including ipilimumab for locally advanced NSCLC was feasible and well tolerated with limited toxicity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lung Cancer

DOI

EISSN

1872-8332

Publication Date

August 2016

Volume

98

Start / End Page

76 / 78

Location

Ireland

Related Subject Headings

  • Treatment Outcome
  • Radiotherapy, Adjuvant
  • Radiotherapy Dosage
  • Postoperative Care
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Ipilimumab
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boyer, M. J., Gu, L., Wang, X., Kelsey, C. R., Yoo, D. S., Onaitis, M. W., … Salama, J. K. (2016). Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer, 98, 76–78. https://doi.org/10.1016/j.lungcan.2016.05.014
Boyer, Matthew J., Lin Gu, Xiaofei Wang, Chris R. Kelsey, David S. Yoo, Mark W. Onaitis, Frank R. Dunphy, Jeffrey Crawford, Neal E. Ready, and Joseph K. Salama. “Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.Lung Cancer 98 (August 2016): 76–78. https://doi.org/10.1016/j.lungcan.2016.05.014.
Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, et al. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer. 2016 Aug;98:76–8.
Boyer, Matthew J., et al. “Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.Lung Cancer, vol. 98, Aug. 2016, pp. 76–78. Pubmed, doi:10.1016/j.lungcan.2016.05.014.
Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, Dunphy FR, Crawford J, Ready NE, Salama JK. Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. Lung Cancer. 2016 Aug;98:76–78.
Journal cover image

Published In

Lung Cancer

DOI

EISSN

1872-8332

Publication Date

August 2016

Volume

98

Start / End Page

76 / 78

Location

Ireland

Related Subject Headings

  • Treatment Outcome
  • Radiotherapy, Adjuvant
  • Radiotherapy Dosage
  • Postoperative Care
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Ipilimumab